Researchers found 39% of GLP-1 users reported nail detachment, compared with 9% of non-users. The authors stress the data is self-reported and doesn't prove the drugs cause it.
Recap by typeshit. Full story at Labroots.
Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
Researchers at the American Academy of Ophthalmology meeting found NAION patients on GLP-1 drugs tended to develop it in the other eye sooner.
A short social post suggesting the GLP-1 story goes beyond weight loss and the controversy around these drugs. It's light on specifics, so expect opinion rather than new data.
Michael Miller of TSCG joins The Real Deal's Deconstruct podcast to talk about how GLP-1 drugs could reshape demand for commercial property.
Loading…